You are here: Industry Insights > combination

News List

KEYTRUDA, Chemotherapy Combination Met Primary Endpoint americanpharmaceuticalreview
July 30, 2019
Merck announced the Phase 3 KEYNOTE-522 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy met one of the dual-primary endpoints of pathological complete response (pCR) following the neoadjuvant part of ...
Combination Biopsy Strategy May Identify More Prostate Cancers drugs
June 27, 2019
Combination Biopsy Strategy May Identify More Prostate Cancers.
Combination Therapy for Rosacea Shows Improved Response Rates drugs
June 27, 2019
Combination Therapy for Rosacea Shows Improved Response Rates.
BMS’ Opdivo fails in Phase III glioblastoma trial pharmaceutical-technology
May 13, 2019
Bristol-Myers Squibb (BMS) has announced that its immunotherapy drug Opdivo (nivolumab) has failed to meet its primary endpoint of overall survival (OS) in Phase III CheckMate-498 trial.
Combination therapy ‘favourable’ in long-term acne treatment europeanpharmaceuticalreview
April 30, 2019
According to Rutgers researchers, physicians are scaling back on prescribing antibiotics for long-term acne treatment in favour of a combination of therapies.
Questions about BMS-Celgene integration plans? Obviously. Answers? Not so much fiercepharma
April 29, 2019
Now that shareholders have voted for the deal, Bristol-Myers Squibb faces some serious pressure to prove its Celgene buyout will actually pay off. So it's no wonder analysts are demanding to know...
Ozempic® superior in lowering blood sugar and weight vs placebo, both in combination with SGLT-2 inhibitors worldpharmanews
March 06, 2019
Novo Nordisk announced publication of results from the SUSTAIN 9 Phase 3b trial in The Lancet Diabetes & Endocrinology.
Daiichi Sankyo Europe, Esperion Announce Validation of MAA for Bempedoic Acid and the Bempedoic Acid/Ezetimibe Fixed Dose Combination Tablet americanpharmaceuticalreview
March 01, 2019
Daiichi Sankyo Europe and Esperion Therapeutics announced the validation of the Marketing Authorisation Application (MAA) for bempedoic acid and the bempedoic acid / ezetimibe fixed dose combination tablet by the European Medicines Agency (EMA).
Combination antiplatelet therapy reduces risk of recurrent stroke europeanpharmaceuticalreview
February 13, 2019
A combination therapy using the blood thinner cilostazol, along with either aspirin or clopidogrel, was shown to decrease the risk of stroke recurrence…
USFDA accepts Merck and Pfizer’s sBLA for Renal Cancer drug biospectrumasia
February 13, 2019
The clinical development program for avelumab, known as JAVELIN, involves at least 30 clinical programs and more than 9,000 patients evaluated across more than 15 different tumor types.

Previous page 1 2 Next page